Filer Snapshot

Lisa Rojkjaer

CIK 0001846460. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Individual

Total filings

19

Latest filing

19 Feb 2026

Industry

n/a

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: Forms 3/4/5 owner position for RIGL. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Open owner activity Save page

Largest parsed holding

—

Populates from the latest parsed 13F information table.

Open holding

13D/G large stake

—

No recent parsed 13D/G stake row for this CIK.

Browse 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC Forms 3/4/5

4 filed on 19 Feb 2026 for CIK 0001846460.

View Source Filing
SEC ownership signals 1 fact
SEC ownership summary

Filing-value scale

Bars compare parsed values by filing family; they are not one combined total.

Forms 3/4/5 positions$1.38M

Reporting-owner positions when a value can be estimated.

Forms 3/4/5 position value

$1.38M

Estimated from parsed Forms 3/4/5 when the filing discloses enough data.

Top issuer positions

Top parsed positions across ownership filing types.

RIGL VIRX
How to read these values
  • Filing families stay separate: 13F portfolio value, 13D/G large stakes, and Forms 3/4/5 owner positions should not be blended into one total.
  • Use the linked research paths to verify each signal against the original SEC filing.
Filer identity 1 fact
Business address
C/O Viracta Therapeutics, Inc., 2533 South Coast Hwy., Ste. 210, Cardiff, CA, 92007

Filer intelligence

What SEC filings say about Lisa Rojkjaer

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Save filer

Quick read

  • Forms 3/4/5 show insider context for RIGL worth $1.31M.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio No rows yet

Quarterly institutional portfolio holdings.

Open
13D/G stakes No rows yet

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 2 rows

Officer, director, and 10% owner holdings or transactions.

Open

Forms 3/4/5 insider context

RIGL

17 Feb 2026 · EVP, Chief Medical Officer

$1.31M
Issuer page Owner page

VIRX

16 Mar 2023 · Chief Medical Officer

$77.6K
Issuer page Owner page

Latest update

What changed recently for Lisa Rojkjaer

Ownership report updated

Latest ownership report period: 17 Feb 2026. Open the source-backed page to inspect the fresh filing or facts context.

Update date

19 Feb 2026

Page type

Ownership filings

Latest period

17 Feb 2026

Ownership context was refreshed from SEC Forms 3/4/5 filed on 19 Feb 2026.

Open ownership filings Browse recent public updates

SEC filing record

CIK 0001846460 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
19
First seen
24 Feb 2021
Latest filing
19 Feb 2026
Entity
Individual

Observed form types

4 3 144

Primary evidence

Open SEC filing index Lisa Rojkjaer SEC filings Lisa Rojkjaer owner filings

Latest Filings

Showing the latest 12 of 19 SEC filings for Lisa Rojkjaer.

Open full filing history
4 File 000-29889

FORM 4

Filing date
19 Feb 2026
Reporting date
17 Feb 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 000-29889

FORM 4

Filing date
12 Feb 2026
Reporting date
10 Feb 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 000-29889

4 filing

Filing date
17 Sep 2025
Reporting date
15 Sep 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 000-29889

4 filing

Filing date
19 Mar 2025
Reporting date
17 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 000-29889

4 filing

Filing date
31 Jan 2025
Reporting date
29 Jan 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 000-29889

4 filing

Filing date
29 Mar 2024
Reporting date
27 Mar 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
3 File 000-29889

3 filing

Filing date
29 Mar 2024
Reporting date
27 Mar 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 000-51531

FORM 4 SUBMISSION

Filing date
17 Mar 2023
Reporting date
16 Mar 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 000-51531

FORM 4 SUBMISSION

Filing date
28 Feb 2023
Reporting date
25 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 000-51531

FORM 4 SUBMISSION

Filing date
29 Nov 2022
Reporting date
25 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 000-51531

FORM 4 SUBMISSION

Filing date
29 Aug 2022
Reporting date
25 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 000-51531

FORM 4 SUBMISSION

Filing date
27 May 2022
Reporting date
25 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .